These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 32805167)
1. After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleeding. Mukherjee D Ann Intern Med; 2020 Aug; 173(4):JC22. PubMed ID: 32805167 [TBL] [Abstract][Full Text] [Related]
2. Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Yuan Z; Levitan B; Deng H; Szarek M; Bauersachs RM; Berkowitz SD; Haskell L; Barnathan ES; Bonaca MP J Am Heart Assoc; 2024 Apr; 13(8):e032782. PubMed ID: 38563380 [TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in peripheral artery disease: The new kid on the block? Hussain MA; Verma S; Al-Omran M J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208 [No Abstract] [Full Text] [Related]
4. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Eikelboom JW; Bosch JJ; Connolly SJ; Shestakovska O; Dagenais GR; Hart RG; Leong DP; O'Donnell M; Fox KAA; Bhatt DL; Cairns JA; Tasto C; Berkowitz SD; Cook Bruns N; Muehlhofer E; Diaz R; Maggioni AP; Yusuf S J Am Coll Cardiol; 2019 Sep; 74(12):1519-1528. PubMed ID: 31537259 [TBL] [Abstract][Full Text] [Related]
5. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Capell WH; Bonaca MP; Nehler MR; Chen E; Kittelson JM; Anand SS; Berkowitz SD; Debus ES; Fanelli F; Haskell L; Patel MR; Bauersachs R; Hiatt WR Am Heart J; 2018 May; 199():83-91. PubMed ID: 29754671 [TBL] [Abstract][Full Text] [Related]
6. VOYAGER PAD contributes to medical therapy for peripheral artery disease. Farber A J Vasc Surg; 2020 Dec; 72(6):1843-1844. PubMed ID: 33222822 [No Abstract] [Full Text] [Related]
7. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease? Boden WE; Bhatt DL Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448 [No Abstract] [Full Text] [Related]
8. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. Ambler GK; Nordanstig J; Behrendt CA; Twine CP Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837 [No Abstract] [Full Text] [Related]
9. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S; Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879 [TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease. Wheeler M; Chan N; Eikelboom J Future Cardiol; 2020 Nov; 16(6):597-611. PubMed ID: 32633570 [TBL] [Abstract][Full Text] [Related]
11. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Gibler WB Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312 [No Abstract] [Full Text] [Related]
12. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease. Coleman CI; Baker WL; Meinecke AK; Eriksson D; Martinez BK; Bunz TJ; Alberts MJ Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):159-166. PubMed ID: 31549153 [TBL] [Abstract][Full Text] [Related]
14. Identifying the highest risk vascular patients: Insights from the XATOA registry. Anand SS; Aboyans V; Bosch J; Debus S; Gay A; Patel MR; Vogtländer K; Welsh RC; Zeymer U; Fox KAA; Am Heart J; 2024 Mar; 269():191-200. PubMed ID: 38218425 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023 [TBL] [Abstract][Full Text] [Related]